MXPA04001886A - Derivados de piperidina utiles como antagonistas de ccr5. - Google Patents

Derivados de piperidina utiles como antagonistas de ccr5.

Info

Publication number
MXPA04001886A
MXPA04001886A MXPA04001886A MXPA04001886A MXPA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A MX PA04001886 A MXPA04001886 A MX PA04001886A
Authority
MX
Mexico
Prior art keywords
compound
treatment
combination
derivatives useful
piperidine derivatives
Prior art date
Application number
MXPA04001886A
Other languages
English (en)
Inventor
W Miller Michael
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MXPA04001886A publication Critical patent/MXPA04001886A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Molecular Biology (AREA)
  • Psychiatry (AREA)
  • Transplantation (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion provee un compuesto de formula (I) (ver formula) o una de sus sales o solvatos aceptables farmaceuticamente, en la cual R1, R2, R3, R9, R10, A y B son como se definio en la especificacion; la presente invencion tambien provee composiciones farmaceuticas que contienen el compuesto de la invencion, y metodos de tratamiento que utilizan el compuesto de la invencion; la invencion tambien se refiere al uso de una combinacion de un compuesto de esta invencion y uno o mas agentes antivirales u otros agentes utiles en el tratamiento del virus de lnmunodeficiencia Humana (VIH); la invencion se refiere asimismo al uso de un compuesto de esta invencion, solo o en combinacion con otro agente, en el tratamiento del rechazo al trasplante de organos solidos, de la enfermedad injerto vs. huesped, de la artritis, de la artritis reumatoide, de la enfermedad inflamatoria del intestino, de la dermatitis atopica, de la soriasis, del asma, de las alergias o de la esclerosis multiple.
MXPA04001886A 2001-08-29 2002-08-28 Derivados de piperidina utiles como antagonistas de ccr5. MXPA04001886A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31568301P 2001-08-29 2001-08-29
PCT/US2002/027389 WO2003020716A1 (en) 2001-08-29 2002-08-28 Piperidine derivatives useful as ccr5 antagonists

Publications (1)

Publication Number Publication Date
MXPA04001886A true MXPA04001886A (es) 2004-06-15

Family

ID=23225580

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA04001886A MXPA04001886A (es) 2001-08-29 2002-08-28 Derivados de piperidina utiles como antagonistas de ccr5.

Country Status (24)

Country Link
US (4) US20040010008A1 (es)
EP (1) EP1421075B1 (es)
JP (2) JP4223950B2 (es)
KR (1) KR20040029057A (es)
CN (1) CN1304389C (es)
AR (1) AR036366A1 (es)
AT (1) ATE328879T1 (es)
BR (1) BR0212108A (es)
CA (1) CA2457861A1 (es)
CY (1) CY1105198T1 (es)
DE (1) DE60212146T2 (es)
DK (1) DK1421075T3 (es)
EC (1) ECSP044993A (es)
ES (1) ES2264491T3 (es)
HK (1) HK1061563A1 (es)
HU (1) HUP0402019A3 (es)
IL (1) IL160060A0 (es)
MX (1) MXPA04001886A (es)
NO (1) NO20041266L (es)
PL (1) PL368827A1 (es)
PT (1) PT1421075E (es)
RU (1) RU2004109510A (es)
WO (1) WO2003020716A1 (es)
ZA (1) ZA200401594B (es)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds
EP1404667B1 (en) 2001-07-02 2006-03-08 AstraZeneca AB Piperidine derivatives useful as modulators of chemokine receptor activity
SE0200844D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
SE0200843D0 (sv) 2002-03-19 2002-03-19 Astrazeneca Ab Chemical compounds
GB0223223D0 (en) * 2002-10-07 2002-11-13 Novartis Ag Organic compounds
US20040082612A1 (en) 2002-10-15 2004-04-29 Baxter Ellen W Benzyl substituted (piperidin-4-yl)aminobenzamido derivatives
SE0300957D0 (sv) 2003-04-01 2003-04-01 Astrazeneca Ab Chemical compounds
CN101798299A (zh) * 2003-11-03 2010-08-11 先灵公司 用作趋化因子受体抑制剂的双六氢吡啶衍生物
WO2005047249A1 (en) * 2003-11-10 2005-05-26 Schering Aktiengesellschaft Benzylether amine compounds useful as ccr-5 antagonists
JP4948395B2 (ja) 2004-04-13 2012-06-06 インサイト・コーポレイション ケモカインレセプターアンタゴニストとしてのピペラジニルピペリジン誘導体
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
WO2006071958A1 (en) * 2004-12-29 2006-07-06 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
WO2006077499A1 (en) * 2005-01-20 2006-07-27 Pfizer Limited Chemical compounds
US7705019B2 (en) * 2005-02-23 2010-04-27 Schering Corporation Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
US20070010565A1 (en) * 2005-04-25 2007-01-11 Olaf Prien New thiazolidinones without basic nitrogen, their production and use as pharmaceutical agents
CA2615650A1 (en) 2005-07-21 2007-01-25 Astrazeneca Ab Novel piperidine derivatives
US8119661B2 (en) * 2007-09-11 2012-02-21 Astrazeneca Ab Piperidine derivatives and their use as muscarinic receptor modulators
RU2010116821A (ru) * 2007-10-01 2011-11-10 Ф.Хоффманн-Ля Аг (Ch) N-гетероциклические биарильные карбоксамиды в качестве антагонистов рецептора ccr
WO2009153182A1 (en) * 2008-06-18 2009-12-23 F. Hoffmann-La Roche Ag Novel heteroaryl carboxamide derivatives
GB201017345D0 (en) 2010-10-14 2010-11-24 Proximagen Ltd Receptor antagonists
EP3083594A1 (de) 2013-12-19 2016-10-26 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenorezeptor alpha 2c antagonisten
WO2015091417A1 (de) 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte piperidinyl-tetrahydrochinoline
JOP20200052A1 (ar) 2013-12-19 2017-06-16 Bayer Pharma AG بيبريدينيل تتراهيدرو كوينولينات مستبدلة واستخدامها كمعضدات مستقبل أدريني ألفا- 2c
WO2015091420A1 (de) * 2013-12-19 2015-06-25 Bayer Pharma Aktiengesellschaft Substituierte bipiperidinyl-derivate als adrenrezeptor alpha 2c antagonisten
JP6927882B2 (ja) 2015-04-02 2021-09-01 プロキシマジェン，リミティド ライアビリティ カンパニー 癌の新治療法
US11629196B2 (en) 2020-04-27 2023-04-18 Incelldx, Inc. Method of treating SARS-CoV-2-associated hypercytokinemia by administering a human monoclonal antibody (PRO-140) that inhibits CCR5/CCL5 binding interactions

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4588722A (en) * 1984-01-09 1986-05-13 Janssen Pharmaceutica N.V. N-(4-piperidinyl) bicyclic condensed 2-imidazolamine derivatives
TW531537B (en) * 1995-12-27 2003-05-11 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4-substituted piperidine derivatives
DK0912515T3 (da) * 1996-07-10 2003-03-10 Schering Corp 1,4-Disubstituerede piperidiner som muscarinantagonister
US5952349A (en) * 1996-07-10 1999-09-14 Schering Corporation Muscarinic antagonists for treating memory loss
HUP0203528A3 (en) * 1999-05-04 2003-11-28 Schering Corp Piperidine derivatives useful as ccr5 antagonists, pharmaceutical compositions containing them and their use
WO2001030348A1 (en) * 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
AR033517A1 (es) * 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0108876D0 (en) * 2001-04-09 2001-05-30 Novartis Ag Organic Compounds

Also Published As

Publication number Publication date
CY1105198T1 (el) 2010-03-03
US20040092745A1 (en) 2004-05-13
ECSP044993A (es) 2004-04-28
CA2457861A1 (en) 2003-03-13
DE60212146D1 (de) 2006-07-20
HUP0402019A2 (hu) 2005-02-28
HK1061563A1 (en) 2004-09-24
EP1421075B1 (en) 2006-06-07
PL368827A1 (en) 2005-04-04
EP1421075A1 (en) 2004-05-26
RU2004109510A (ru) 2005-10-20
JP2008222722A (ja) 2008-09-25
DE60212146T2 (de) 2007-06-06
KR20040029057A (ko) 2004-04-03
US8034933B2 (en) 2011-10-11
US20040010008A1 (en) 2004-01-15
NO20041266L (no) 2004-03-26
IL160060A0 (en) 2004-06-20
ATE328879T1 (de) 2006-06-15
ES2264491T3 (es) 2007-01-01
JP4223950B2 (ja) 2009-02-12
US7442703B2 (en) 2008-10-28
US20080214575A1 (en) 2008-09-04
US7384948B2 (en) 2008-06-10
US20040092551A1 (en) 2004-05-13
WO2003020716A1 (en) 2003-03-13
HUP0402019A3 (en) 2009-07-28
CN1304389C (zh) 2007-03-14
DK1421075T3 (da) 2006-09-18
ZA200401594B (en) 2004-11-24
PT1421075E (pt) 2006-10-31
AR036366A1 (es) 2004-09-01
BR0212108A (pt) 2004-08-24
JP2005502682A (ja) 2005-01-27
CN1551877A (zh) 2004-12-01

Similar Documents

Publication Publication Date Title
MXPA04001886A (es) Derivados de piperidina utiles como antagonistas de ccr5.
TR200402496T2 (tr) CCR5 antagonistleri olarak yararlı piperidin türevleri.
CA2371583A1 (en) Piperazine derivatives useful as ccr5 antagonists
RS101304A (sr) Indolni, azaindolni i srodni heterociklični 4-alkenil piperidinski amidi
MY132106A (en) New pyridazin-3(2h)-one derivatives
DE602004024375D1 (de) Carboxamidderivate
TW200504067A (en) New substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
MY137535A (en) New pyrrolidinium derivatives
HRP20040317A2 (en) 1,8-naphthyridine derivatives as antidiabetics
WO2005049581A8 (en) Pyridazin-3 (2h) -one derivatives and their use as pde4 inhibitors
WO2002083667A3 (en) Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
SE0302116D0 (sv) Novel compounds
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
DE602004011966D1 (en) Heterocyclylverbindungen
MXPA04004263A (es) Hidrazono-malonitrilos.
WO2003106450A8 (de) Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
TNSN97014A1 (fr) Piperidones, procedes pour leur preparation et compositions pharmaceutiques les contenant.
MY147899A (en) Piperidine derivatives useful as ccr5 antagonists
AU2001290480A1 (en) Cyclized benzamide neurokinin antagonists for use in therapy
TW200616636A (en) Novel compounds
WO2005042517A3 (en) Bipiperidinyl derivatives useful as inhibitors of chemokine receptors
TW200745087A (en) CCR5 antagonists useful for treating HIV
TW200640910A (en) Piperidinyl piperazine derivatives useful as inhibitors of chemokine receptors
TW200640909A (en) Piperidinyl piperidine derivatives useful as inhibitors of chemokine receptors
ATE272642T1 (de) Thieno(2,3-d)pyrimidindione und ihre verwendung als pharmazeutische mittel

Legal Events

Date Code Title Description
FG Grant or registration